It has been suggested that vitamin D has a role in the pathogenesis and regulation of inflammatory bowel disease (IBD). However, physicians inconsistently obtain vitamin D levels in IBD patients for unclear reasons. It is speculated that the severity of the disease may influence physicians’ vitamin D testing. This study evaluated whether the frequency of vitamin D assessments occurred more often in patients maintained on biologic (BIO) and/or immunosuppressants (IM) therapy compared to aminosalicylates (ASA).